Comparison · NCT04206553-007142e2
Dupilumab Q2W vs Placebo: Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dupilumab Q2W vs Placebo: Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52. Trial comparisons, record NCT04206553-007142e2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04206553-007142e2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.962 | 0.872 | 0.99 | wilson | |
| Risk in group 2 | 0.962 | 0.872 | 0.99 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0939 | 0.0939 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.927 | 1.08 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.136 | 7.37 | log | |
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dupilumab Q2W | Participants received a dupilumab loading dose administered SC, followed by a SC dose Q2W | 51 | 53 | OG001 |
| Group 2 | Placebo | Participants received a dupilumab-matching placebo loading dose administered SC, followed by a SC dose Q2W | 51 | 53 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52
- Description
- Time frame
- Through Week 52
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
- NCT number
- NCT04206553
- Phases
- PHASE2, PHASE3
- Conditions
- Bullous Pemphigoid
- Interventions
- dupilumab, Matching Placebo, Oral corticosteroids (OCS)
- Lead sponsor
- Regeneron Pharmaceuticals
- Results first posted
- 2026-03-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04206553?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04206553-007142e2